Navigation Links
GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
Date:7/3/2008

LIBERTY CORNER, N.J., July 3 /PRNewswire/ -- On June 27, 2008 GeneraMedix Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Epoprostenol for Injection 1.5 mg New Drug Application (NDA).

Epoprostenol for Injection 1.5 mg is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

GeneraMedix Epoprostenol for Injection is available in 10 mL vials containing lyophilized epoprostenol sodium equivalent to 1.5 mg of epoprostenol. When reconstituted and diluted for administration with Water for Injection or Sodium Chloride Injection, the infusion solution is stable for up to 24 hours at room temperature. GeneraMedix's product differs from other currently available epoprostenol formulations, which require a special diluent and gel packs in a cold pouch in order to maintain stability for 24 hours.

Ronald F. Quadrel, President and CEO of GeneraMedix Inc. stated, "We are very excited with the FDA approval of our Epoprostenol for Injection. We feel that the advantages of our product may improve the ease of use, and more importantly, may help to improve the quality of life for patients with the most severe cases of pulmonary arterial hypertension. The addition of Epoprostenol for Injection to our cadre of FDA approved products fits well with our overall objective of providing injectable drugs that are difficult to source or manufacture while providing benefits for patients."

About GeneraMedix Inc.

GeneraMedix Inc. is a pharmaceutical company offering high quality injectable generic products to the hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review.
'/>"/>

SOURCE GeneraMedix Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...test pilots push planes to explore their limits, r...and Technology (NIST) are probing the newest micro...curacy at the nanoscale. Better nanoscale measurem...ing production in the semiconductor and nanomanufa...logy uses helium ions to generate the signal used ...
(Date:9/5/2008)...e Food & Drug Administration (FDA) issued in July ...port acknowledged that nanoscale materials potenti... by the agency and that those materials present ch...elevant to product safety and effectiveness may ch...icipating the potential for rapid commercializatio...
(Date:9/5/2008)...us, gold is only valuable if we possess it in larg...le isn,t the case for those interested in exploiti...ariety of chemical reactions, including the oxidat...s carbon dioxide at room temperatures. That proces...e effectiveness of catalytic converters that clean...
(Date:9/5/2008)...ept. 5 /- Gen-Probe Incorpo...mpany will present at the Morgan,Stanley Global He...r 9,2008 at approximately 2:45 p.m. Eastern Time....and may be accessed through a link on the investor...n-probe.com . The webcast,will be available for 30...
Breaking Biology Technology:NIST studies how new helium ion microscope measures up 2Nanotechnology and the FDA: size matters 2NIST and partners identify tiny gold clusters as top-notch catalysts 2Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference 2
...ds treasures in decidedly unromantic spots like li...managing director at Milwaukee-based private equit...,And though Mason Wells typically devotes its IT v...h potential, D,Souza likes to beat the bushes at e... at Madison,s Fluno Center because one never know...
...identification tags "wake up" when they,re near a ...duct information, including its history, quantity,... elsewhere, hundreds of major companies are scurry...requency identification (RFID) technology after fa...ment of Defense that their suppliers be RFID-compl...
...-profit in Texas that helps match charitable corpo...has named former Wisconsin governor Scott McCallum...n in 2000 through a software donation from I2 Tec...e then it has crafted Internet-based methods of ge...n groups. In 2001 Aidmatrix worked with an interna...
... Po-Ling Loh at Memorial High in Madison, Wisconsi...uld find use in security and cryptography applicat...Talent Search for her project on "closed embedding...ere handed out in Washington, D.C., on Tuesday to ...,000 went to a New York student for a device that ...
Other Biology Technology:Successful Wisconsin VC sets sights on data integration and mass storage 2Successful Wisconsin VC sets sights on data integration and mass storage 3UW-Madison workgroup helps state companies tap the power of RFID 2UW-Madison workgroup helps state companies tap the power of RFID 3UW-Madison workgroup helps state companies tap the power of RFID 4Online aid group taps former Wisconsin governor McCallum 2Online aid group taps former Wisconsin governor McCallum 3
(Date:9/5/2008)...nformatics will convene September 7-9 at the Stock...ging neuroinformatics field combines neuroscience ... and approaches to understanding the structure and...ied to brain disorders and diseases. With a broad ...ether experts from all disciplines contributing to...
(Date:9/5/2008)... face the challenge of surviving in a changing cli...niversit Claude Bernard Lyon have shown how a shee... of Scotland responds to two consequences of clima...dictability of winter storms. Dr. Thomas Ezard, le...good and food is plentiful, lambs contribute almos...
(Date:9/5/2008)... Hurricane Gustav is shown via a sequence of satel...n Imaging Spectrometer (MERIS) instrument on 25 Au...rom right to left). , Gustav formed on 25 August...ti (seen above far right image), when a tropical w...feature (visible), causing the U.S. National Hurri...
(Date:9/4/2008)....D. Anderson Cancer Center have developed a risk p...for African Americans that suggests a greater risk..., according to a report published in the September...of the American Association for Cancer Research. ...rican Americans with lung cancer and 497 African A...
Breaking Biology News(10 mins):INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2Hurricane Gustav 2African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease 2Manipulating the immune system like a parasite 16341 1Manipulating the immune system like a parasite 16341 2Alsius Corporation Awarded Three Year Agreement With MedAssets Supply Chain Systems 16338 1Alsius Corporation Awarded Three Year Agreement With MedAssets Supply Chain Systems 16338 2Alsius Corporation Awarded Three Year Agreement With MedAssets Supply Chain Systems 16338 3Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting 16333 1Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting 16333 2New Therapy by Merck is Positioned to Earn Gold Standard Status by 2011 in the Treatment of Chemotherapy Induced Nausea and Vomiting 4489 1New Therapy by Merck is Positioned to Earn Gold Standard Status by 2011 in the Treatment of Chemotherapy Induced Nausea and Vomiting 4489 2New Therapy by Merck is Positioned to Earn Gold Standard Status by 2011 in the Treatment of Chemotherapy Induced Nausea and Vomiting 4489 3
...searchers are recruiting people with backache caus...?in the first ever study to discover if therapeuti...opher McCarthy and his team at the University,s Ce... aged 22-55 who have had sciatica for less than 12... spinal surgery. , The volunteers will receive ...
...ch tools, researchers have identified three protei...ection up to 20 months before the rejection occurr...rtality rate of organ recipients, about 45% over f...t Chris Wendt. Currently, there is no reliable way...signs of chronic rejection appear, it is usually t...
... important for the survival of many types of cells... neurons ?critical brain cells that connect the ce... motor neuron diseases like amyotrophic lateral sc...ember 2006 issue of Nature Neuroscience, two inves... and the Harvard Stem Cell Institute describe how ...
...mune system controls HIV during the earliest phase...fic versions of key immune-system molecules called...on the fragments of viral protein those molecules ...infected cells. In a report in the November issue...IDS Research Center at Massachusetts General Hospi...
Other Biology News:Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3Growth factor stimulates rapid extension of key motor neurons in brain 2Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
...Maker, 1. Modular system for large format and medi...b-cast or precast gels (26 x 20 cm) simultaneously...mple-to-use 1.0-mm or 1.5-mm pre-assembled hinged ... and unloading.Built-in ceramic heat exchanger and...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day.
Request Info
MOUSE ANTI HUMAN FACTOR I
Biology Products: